Somatuline Lanreotide Acetate Sustained-release Injection

1. Indications and Usage
Acromegaly:
Indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to, or cannot be treated with, surgery and/or radiotherapy. It is used to reduce Growth Hormone (GH) and IGF-1 levels.
Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs):
Indicated for the treatment of adult patients with unresectable, well-differentiated, locally advanced or metastatic GEP-NETs to prolong progression-free survival.
Carcinoid Tumors:
Indicated for the symptomatic control of carcinoid syndrome (e.g., flushing and diarrhea).
2. Dosage and Administration
Route of Administration:
For Deep Subcutaneous Injection ONLY.
Injection Site: Must be administered into the upper outer quadrant of the buttock (gluteal region).
Technique: The injection should be deep subcutaneous (not intramuscular). The needle must be inserted fully, perpendicular to the skin, without pinching the skin.
Recommended Dosage:
Acromegaly:
Initial: 90 mg every 4 weeks.
Adjustment: After 3 months, dosage may be adjusted (60 mg, 90 mg, or 120 mg) based on GH and IGF-1 levels. If well-controlled on 60 mg or 90 mg, the dosing interval can be extended to every 6 or 8 weeks with 120 mg.
GEP-NETs:
120 mg every 4 weeks.
Special Populations:
Renal/Hepatic Impairment: For moderate-to-severe impairment, the initial dose should be 60 mg every 4 weeks.
3. Mechanism of Action
Synthetic Analogue:
Lanreotide is a long-acting octapeptide analogue of natural somatostatin.
Somatostatin Receptor Binding:
It binds to somatostatin receptors (particularly subtypes 2 and 5) on pituitary somatotroph cells and neuroendocrine tumor cells.
Inhibition of Secretion:
It inhibits the excessive secretion of Growth Hormone (GH) and various gastrointestinal peptides (e.g., gastrin, VIP) via G-protein coupled signaling pathways.
Autogel Technology:
The formulation utilizes a bio-adhesive gel matrix that allows for a consistent, controlled release of the drug over 28 days from a subcutaneous depot.
4. Safety and Warnings
Gallbladder Abnormalities:
Cholelithiasis (gallstones) or biliary sludge is a common adverse reaction due to inhibition of gallbladder contractility. Baseline and periodic (every 6–12 months) biliary ultrasound is recommended.
Glucose Regulation:
Lanreotide may inhibit insulin and glucagon secretion, potentially leading to hyperglycemia or hypoglycemia. Blood glucose should be monitored, and antidiabetic therapy adjusted as needed.
Cardiac Conduction:
Bradycardia has been reported. Caution is advised in patients with pre-existing cardiac conditions.
Injection Site Reactions:
Pain, nodule formation, or induration at the injection site may occur.
5. Adverse Reactions
Gastrointestinal:
Diarrhea, abdominal pain, nausea, constipation, flatulence, and steatorrhea.
Hepatobiliary:
Cholelithiasis (usually asymptomatic), cholestasis, gallbladder polyps.
Metabolic:
Hyperglycemia, hypoglycemia, hypothyroidism.
Cardiovascular:
Sinus bradycardia.
6. Drug Interactions
Cyclosporine:
May decrease the intestinal absorption of cyclosporine, potentially requiring dose increases.
Antidiabetic Agents:
May alter the efficacy of insulin and oral hypoglycemic agents; frequent glucose monitoring is essential.
Beta-Blockers:
Additive effects on heart rate may occur when used with agents that induce bradycardia.
7. Pharmaceutical Information
Chemical Composition:
Active Ingredient: Lanreotide acetate.
Appearance: White to off-white semi-solid gel in a pre-filled syringe.
Storage:
Store in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original package to protect from light.